BSPM News Alert Biostar Pharmaceuticals (BSPM) 1.09 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biostar Pharmaceuticals (BSPM) 1.09 $BSPM

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:46AM CST

ZIOP: 4.76 (+0.07), BSPM: 1.09 (-0.03), BDR: 2.36 (+0.06), ZAZA: 3.20 (+0.70), ACY: 8.50 (-0.05), NBS: 3.27 (+0.02), SYRX: 1.14 (+0.11), IAG: 2.41 (+0.06), THTI: 1.32 (+0.14), BITA: 72.57 (+0.36), VRTB: 3.49 (-0.12), OPTT: 0.63 (-0.01), INVT: 0.63 (+0.04), GERN: 3.06 (+0.05), VASC: 27.30 (+0.71), LOCM: 1.15 (+0.03), CTHR: 1.63 (-0.03), MOV: 27.58 (-0.41), IFON: 1.07 (-0.06), SVM: 1.25 (+0.09)

Biostar Pharma revenues down in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:00AM CST

BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals EPS of $0.02
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:08AM CST

BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Fri Nov 14, 8:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the third quarter ended September 30, 2014.
BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals, Inc. Files a PRC Patent Application for Oleanolic Acid Injection, its New Drug Product for Hepatitis B and Liver Cancer
PR Newswire - Thu Sep 18, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or the "Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today it has filed PRC national invention and creation patent for the pharmaceutical and preparation method of its new developed product, Oleanolic Acid Injection, which designed to treat Hepatitis B and liver cancer. The application passed the preliminary examination of the PRC State Intellectual Property Bureau and was accepted for review; the application acceptance number is 201410182757.7.
BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals elects Professor Xiaohui Zheng as its chief scientist
M2 - Thu Aug 28, 7:11AM CDT
Pharmaceutical company Biostar Pharmaceuticals (NasdaqCM:BSPM) said on Wednesday that Professor Xiaohui Zheng has been named as its chief scientist to preside over its product development projects.
BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals Inc. Engaged Chief Scientist Professor Xiaohui Zheng To Preside Over The Company's Product Development Projects
PR Newswire - Wed Aug 27, 7:00AM CDT
XIANYANG, China, Aug. 27, 2014 /PRNewswire/-- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that the Company has hired Professor Xiaohui Zheng as its chief scientist to preside over the Company's product development projects.
BSPM: 1.09 (-0.03)

Nasdaq stocks posting largest volume increases
AP - Thu Aug 21, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
PNTR: 7.96 (+0.04), BSPM: 1.09 (-0.03), LNDC: 13.96 (-0.15), HPJ: 5.03 (+0.14), HMPR: 1.72 (+0.02), IMCB: 20.00 (+0.31), BSQR: 4.49 (+0.02), DGLY: 15.62 (+0.82), MGYR: 8.40 (+0.02)

Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
BSPM: 1.09 (-0.03), BAX: 74.45 (-0.04), PFE: 31.42 (-0.03), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), SVA: 4.95 (+0.07), SNY: 46.35 (+0.50), CPHI: 0.38 (+0.01)

Biostar Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 14, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the second quarter ended June 30, 2014.
BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals announces formation of hospital marketing team to open new sales channels in ten provinces in China
M2 - Tue Aug 05, 6:16AM CDT
Health supplement company Biostar Pharmaceuticals (NasdaqCM:BSPM) reported on Monday the establishment a dedicated sales and marketing team for developing and expanding the sales of its Huangyangning tablets, hyperthyroidism and Wenweishu capsules in ten provinces in China.
BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals Inc. Established a Sales and Marketing Task Team to Promote Sales to Hospital Facilities in Ten PRC Provinces
PR Newswire - Mon Aug 04, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that it established a dedicated sales and marketing team for the purposes of developing and eventually expanding sales of the Company's Huangyangning tablets, hyperthyroidism and Wenweishu capsules to the top two tiered hospital facilities in ten PRC provinces, including, among others, in Beijing, Chongqing, Heilongjiang, Hebei and Henan provinces. To that end, in July 2014, the Company's opened a sales office in the high-tech development zone of Xi'an, the capital of Shaanxi province, which office, under the experienced management, will be primarily tasked with preparing sales and marketing team of as many as 200 sales representatives to target the top two tiered hospital facilities in the above-referenced PRC provinces.
BSPM: 1.09 (-0.03)

Biostar Held Its Strategic Development Seminar; Identified Development Planning for 2014 - 2016
PR Newswire - Fri Feb 14, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on February 5, 2014, the Company's Chairman and CEO, Mr. Ronghua Wang, held a development strategy seminar with the management of the Company, at which he outlined the Company's development strategy for the period of 2014-2016 and intended steps to implement this strategy.
BSPM: 1.09 (-0.03)

Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the Shaanxi Province Liver Disease Health Education Base
PR Newswire - Wed Jan 15, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its PRC operating subsidiary was designated as the Shaanxi Province Liver Disease Health Education Base.
BSPM: 1.09 (-0.03), AXN: 0.31 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 47

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 61

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 62

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 133

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 113

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading

Top 5 Most Recently Viewed Articles

Sarepta Therapeutics Faces Class Action Lawsuit: Key Facts

Updated Category News Views 222

Understanding the Recent Class Action Against Sarepta Therapeutics The law firm of Kessler Topaz Meltzer & Check, LLP has announced an important development for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT). A securities class action lawsuit has been filed in the Southern District of New York, which impacts those who purchased or otherwise acquired Sarepta's...

Continue Reading
Honoring Dr. Marvin Boomer Jr. and Advocating for Justice

Updated Category News Views 459

A Community's Tribute to Dr. Marvin Boomer Jr. Today we unite not just in sorrow but in a fierce dedication to remember Dr. Marvin Boomer Jr. His life, marked by brilliance and inspiration, serves as a beacon for many. As we reflect on his contributions, we recognize the larger struggles that affect our community. The Impact of Dr. Boomer's Legacy Dr. Marvin Boomer Jr....

Continue Reading
Key Economic Events and Insights from Kashkari's Speech

Updated Category News Views 154

Anticipating Economic Insights from Kashkari's Address As financial markets gear up for another significant day, numerous crucial economic events are set to occur. Traders are especially keen on the insights that FOMC Member Neel Kashkari may share regarding the Federal Reserve's stance on monetary policy. His speech is expected to potentially guide market reactions and...

Continue Reading
Discover Compelling Dividend Stocks for Investors

Updated Category News Views 126

Exploring Attractive Dividend Stocks The stock market has recently reached several new all-time highs, influenced by a variety of economic factors. While this upward trend has benefited many stocks, it has also limited the number of valuable bargains for investors. However, some companies still stand out as exceptional investment opportunities. Currently, three notable...

Continue Reading
New Housing Initiatives in Canada to Combat Housing Shortage

Updated Category News Views 264

Boosting Housing Availability Across Canada The governments are coming together to tackle the pressing issue of affordable housing in Canada. Their concerted efforts have culminated in a substantial funding package aimed at enhancing the housing landscape. Recently, over $44 million has been dedicated towards constructing more than 280 new homes, further expanding the...

Continue Reading